2386 PURPOSE: The influence of adiposity on muscle strength and size responses to resistance training (RT) is unclear. We compared changes in biceps strength and size of the non-dominant arm in response to RT between normal weight (NW) and overweight (OW) healthy adults. METHODS: Subjects were 140 NW (mean ± SEM) (22.1 ± 0.2 kg/m2, 24.1 ± 0.4 yr) and 81 OW (29.0 ± 0.5 kg/m2, 26.1 ± 0.7 yr) Caucasian men (n = 89) and women (n = 132) who had not performed RT for 1 yr. Subjects underwent 12 wk (2 d/wk) of RT on the non-dominant arm. Biceps muscle strength (kg) was assessed by 1 repetition maximum (1RM) using the single arm curl. Biceps muscle cross sectional area (cm2) was measured using magnetic resonance imaging. Multivariate ANOVA was used to detect differences in muscle strength and size alterations between NW and OW groups. RESULTS: OW volunteers had greater pre-RT absolute biceps strength (10.2 ± 0.3 vs 8.9 ± 0.2kg) and size (20.56 ± 0.42 vs 17.40 ± 0.33cm2) than NW volunteers (p<0.05). Similarly, OW had greater post-RT absolute biceps strength (14.0 ± 0.3 vs 12.8 ± 0.3kg) and size measures (24.27 ± 0.50 vs 20.78 ± 0.39 cm2) than NW subjects, respectively (p<0.05). In contrast, when allometric scaling was applied, NW had greater pre- to post- RT muscle strength gains than OW, 0.31 ± 0.01 vs 0.25 ± 0.01 kg·kg-0.67, respectively (p<0.05). Adjusting muscle size changes for initial values, NW persons tended to have larger pre- to post- RT gains than OW persons, 19.6 ± 0.8 vs 17.9 ± 1.1%, respectively, but these differences did not achieve statistical significance (p≥0.05). CONCLUSION: OW subjects had greater pre- and post- RT absolute muscle strength and size as a result of RT than NW subjects; however, NW experienced greater gains in muscle strength and size than the OW when these responses were adjusted for body weight and initial values, respectively. Our findings suggest excess overall adiposity may attenuate the muscle strength and size responses to RT in apparently healthy, young men and women. Supported by NIH – NINDS RO1 NS40606-02